Rouen Cedex

• A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended recruitment
  2022-501901-10-00 6 2023-02-06 Chronic Hepatitis D Infection
• An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr … Ended recruitment
  2024-510818-33-00 5 2023-01-24 Chronic Spontaneous Urticaria
• Study of the safety and efficacy of treatment venetoclax + azacitidine and donor lymphocyte infusion in patients with MDS or AML in relapse … Ended recruitment
  2024-514877-23-00 9 2022-11-23 Myelodysplastic syndromes or Acute Myeloid Leukemia
• A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Ev … Ended recruitment
  2024-514394-22-00 6 2022-10-24 Actinic Keratosis
• SPLEMENGO - Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies amo … Ended recruitment
  2024-513649-35-00 5 2022-09-15 Asplenia
• A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance … Ended recruitment
  2023-504996-26-00 5 2022-07-21 Metastatic Castration Resistant Prostate Cancer (mCRPC)
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Ended recruitment
  2023-509260-25-00 5 2022-07-12 Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
• A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati … Ended recruitment
  2023-503999-24-00 5 2022-06-01 Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
• IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot … Ended recruitment
  2023-510387-13-00 4 2022-05-18 advanced ALK-positive non-small cell lung cancer
• A study in patients with skin cancer Ended recruitment
  2024-516914-39-00 5 2022-04-27 Metastatic or unresectable melanoma
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and … Ended recruitment
  2024-516403-16-00 5 2022-04-07 Adult patients with immune thrombocytopenia (ITP) with mild to severe
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma … Ended recruitment
  2024-512634-15-00 9 2022-01-05 Patients with untreated mantle cell lymphoma
• VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif … Ended recruitment
  2023-507286-25-00 4 2021-12-23 Diffuse Large B-Cell Lymphoma
• Multi-drug treatment for breast cancer patients with brain metastases Ended recruitment
  2024-510703-11-00 4 2021-12-13 HER2+ metastatic breast cancer with isolated brain progression
• A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat … Ended recruitment
  2023-507698-16-00 5 2021-10-14 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322
• CORTICOP_Comparison of corticosteroids versus placebo on duration of ventilatory support during severe acute exacerbations of COPD patients … Ended recruitment
  2024-516651-41-00 5 2021-10-08 COPD : chronic obstructive Pulmonary disease
• Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung … Ended recruitment
  2024-513770-22-00 4 2021-09-22 Malignant Solid Tumors - Non Small Cell Lung Cancer
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic … Ended recruitment
  2023-506752-24-00 5 2021-08-05 Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh
• A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended recruitment
  2023-507697-40-00 5 2021-07-05 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello- … Ended recruitment
  2023-504997-39-00 5 2021-06-14 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended recruitment
  2023-507132-21-00 10 2021-05-11 Early Parkinson's disease
• Please refer to the full title. Ended recruitment
  2024-516549-37-00 4 2021-04-12 Treatment of Parkinson’s disease (PD)

Showing 313–336 of 469 trials